The document discusses different types of bladder overactivity, either symptomatic or urodynamic, and presents an approach. It notes that not all overactivity is the same. A new pharmacologic approach has opened up the possibility of better adjusted treatments for overactivity, though more work still needs to be done to better define the indications for individual drugs and their combinations.

1. Overactivity;symptomatic ( bladder) or Urodynamic ( detrusor).
An approach. JE Batista. June 2014
“OVERACTIVITY”
Symptomatic (bladder) ““PalpitationsPalpitations””
or
Urodynamic (detrusor):
An approach.
““ ArrithmiasArrithmias””

2. Overactivity;symptomatic ( bladder) or Urodynamic ( detrusor).
An approach. JE Batista. June 2014
“OVERACTIVITY”
Antimuscarinics
Beta-3 agonists

3. Overactivity;symptomatic ( bladder) or Urodynamic ( detrusor).
An approach. JE Batista. June 2014
Not all “overactivity”
is the same.

4. Overactivity;symptomatic ( bladder) or Urodynamic ( detrusor).
An approach. JE Batista. June 2014
DO urgency episodes & urgency rate
functional cap.
BJU int 2013

5. Overactivity;symptomatic ( bladder) or Urodynamic ( detrusor).
An approach. JE Batista. June 2014
u r g e n c y
n o c t u r i a
frequencySymptoms
0
20
40
60
80
100
Approx.
overactive
detrusor
rate
n o c t u r i a

6. Overactivity;symptomatic ( bladder) or Urodynamic ( detrusor).
An approach. JE Batista. June 2014
u r g e n c y
n o c t u r i a
frequencySymptoms a b
d c
0
20
40
60
80
100
Approx.
overactive
detrusor
rate
n o c t u r i a

7. Overactivity;symptomatic ( bladder) or Urodynamic ( detrusor).
An approach. JE Batista. June 2014
“OVERACTIVITY”
New pharmacologic approach opens
the possibility of better adjustedthe possibility of better adjusted
treatments.
Still a long way to better define the
indications of each drug and its
combinations.